MicroRNAs in Head and Neck Squamous Cell Carcinoma: a Possible Challenge As Biomarkers, Determinants for the Choice of Therapy and Targets for Personalized Molecular Therapies

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35116619

Authors

Mahrou Vahabi

Giovanni Blandino

Silvia Di Agostino

Affiliations

Soon will be listed here.

Abstract

Head and neck squamous cell carcinoma (HNSCC) are referred to a group of heterogeneous cancers that include structures of aerodigestive tract such as oral and nasal cavity, salivary glands, oropharynx, pharynx, larynx, paranasal sinuses, and local lymph nodes. HNSCC is characterized by frequent alterations of several genes such as , , , , and as well as copy number increase in , , and . These genomic alterations play a role in terms of resistance to chemotherapy, molecular targeted therapy, and prediction of patient outcome. MicroRNAs (miRNAs) are small single-stranded noncoding RNAs which are about 19-25 nucleotides. They are involved in the tumorigenesis of HNSCC including dysregulation of cell survival, proliferation, cellular differentiation, adhesion, and invasion. The discovery of the stable presence of the miRNAs in all human body made them attractive biomarkers for diagnosis and prognosis or as targets for novel therapeutic ways, enabling personalized treatment for HNSCC. In recent times the number of papers concerning the characterization of miRNAs in the HNSCC tumorigenesis has grown a lot. In this review, we discuss the very recent studies on different aspects of miRNA dysregulation with their clinical significance and we apologize for the many past and most recent works that have not been mentioned. We also discuss miRNA-based therapy that are being tested on patients by clinical trials.

Citing Articles

Exploring the tumor-suppressive role of miRNA-200c in head and neck squamous cell carcinoma: Potential and mechanisms of exosome-mediated delivery for therapeutic applications.

Kishta M, Khamis A, Am H, Elshaar A, Gul D Transl Oncol. 2024; 51:102216.

PMID: 39615277 PMC: 11647223. DOI: 10.1016/j.tranon.2024.102216.

Progress in Precision Medicine for Head and Neck Cancer.

Vakili S, Behrooz A, Whichelo R, Fernandes A, Emwas A, Jaremko M Cancers (Basel). 2024; 16(21).

PMID: 39518152 PMC: 11544984. DOI: 10.3390/cancers16213716.

SCGB1A1 as a novel biomarker and promising therapeutic target for the management of HNSCC.

Wang J, Xu Q, Yu J, Xu A, Yu L, Chen Z Oncol Lett. 2024; 28(5):527.

PMID: 39268163 PMC: 11391500. DOI: 10.3892/ol.2024.14660.

miRNA genetic variations associated with the predisposition of oral squamous cell carcinoma in central Indian population.

Tiwari S, Pandey R, Kumar V, Das S, Gupta V, Nema R Noncoding RNA Res. 2024; 9(4):1333-1341.

PMID: 39131689 PMC: 11315085. DOI: 10.1016/j.ncrna.2024.07.002.

The Relationship of Grade, Stage and Tobacco Usage in Head and Neck Squamous Cell Carcinoma With p53, PIK3CA and MicroRNA Profiles.

Kiran K, Chowdhury N, Singh A, Malhotra M, Kishore S Cureus. 2024; 16(2):e54737.

PMID: 38524071 PMC: 10960946. DOI: 10.7759/cureus.54737.

References

Thomas G, Nadiminti H, Regalado J . Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol. 2005; 86(6):347-63. PMC: 2517451. DOI: 10.1111/j.0959-9673.2005.00447.x. View

Kim E, Kim J, Lee S, Lee H, Yoon J, Hong J . QKI, a miR-200 target gene, suppresses epithelial-to-mesenchymal transition and tumor growth. Int J Cancer. 2019; 145(6):1585-1595. DOI: 10.1002/ijc.32372. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

Blandino G, Di Agostino S . New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018; 37(1):30. PMC: 5815234. DOI: 10.1186/s13046-018-0705-7. View

Tong F, Mao X, Zhang S, Xie H, Yan B, Wang B . HPV + HNSCC-derived exosomal miR-9 induces macrophage M1 polarization and increases tumor radiosensitivity. Cancer Lett. 2020; 478:34-44. DOI: 10.1016/j.canlet.2020.02.037. View

Koshizuka K, Hanazawa T, Arai T, Okato A, Kikkawa N, Seki N . Involvement of aberrantly expressed microRNAs in the pathogenesis of head and neck squamous cell carcinoma. Cancer Metastasis Rev. 2017; 36(3):525-545. DOI: 10.1007/s10555-017-9692-y. View

Zhao Z, Gao D, Ma T, Zhang L . MicroRNA-141 suppresses growth and metastatic potential of head and neck squamous cell carcinoma. Aging (Albany NY). 2019; 11(3):921-932. PMC: 6382419. DOI: 10.18632/aging.101791. View

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H . The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-5. PMC: 3076220. DOI: 10.1038/nm.2284. View

Tang G, Tang X, Mendu V, Tang X, Jia X, Chen Q . The art of microRNA: various strategies leading to gene silencing via an ancient pathway. Biochim Biophys Acta. 2008; 1779(11):655-62. DOI: 10.1016/j.bbagrm.2008.06.006. View

10.

Koshizuka K, Hanazawa T, Fukumoto I, Kikkawa N, Matsushita R, Mataki H . Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma. J Hum Genet. 2016; 62(1):113-121. DOI: 10.1038/jhg.2016.47. View

11.

Lu J, Xu X, Liu X, Peng Y, Zhang B, Wang L . Predictive value of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis. Br J Cancer. 2013; 110(2):392-8. PMC: 3899774. DOI: 10.1038/bjc.2013.751. View

12.

Fu G, Brkic J, Hayder H, Peng C . MicroRNAs in Human Placental Development and Pregnancy Complications. Int J Mol Sci. 2013; 14(3):5519-44. PMC: 3634453. DOI: 10.3390/ijms14035519. View

13.

Nagai H, Hasegawa S, Uchida F, Terabe T, Kanno N, Kato K . MicroRNA-205-5p suppresses the invasiveness of oral squamous cell carcinoma by inhibiting TIMP‑2 expression. Int J Oncol. 2018; 52(3):841-850. DOI: 10.3892/ijo.2018.4260. View

14.

Alsahafi E, Begg K, Amelio I, Raulf N, Lucarelli P, Sauter T . Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis. 2019; 10(8):540. PMC: 6629629. DOI: 10.1038/s41419-019-1769-9. View

15.

Harris T, Jimenez L, Kawachi N, Fan J, Chen J, Belbin T . Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol. 2012; 180(3):917-928. PMC: 3349885. DOI: 10.1016/j.ajpath.2011.12.004. View

16.

He W, Calore F, Londhe P, Canella A, Guttridge D, Croce C . Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci U S A. 2014; 111(12):4525-9. PMC: 3970508. DOI: 10.1073/pnas.1402714111. View

17.

Diaz-Martin J, Diaz-Lopez A, Moreno-Bueno G, Castilla M, Rosa-Rosa J, Cano A . A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J Pathol. 2013; 232(3):319-29. DOI: 10.1002/path.4289. View

18.

Soltani-Sedeh H, Irani S, Mirfakhraie R, Soleimani M . Potential using of microRNA-34A in combination with paclitaxel in colorectal cancer cells. J Cancer Res Ther. 2019; 15(1):32-37. DOI: 10.4103/jcrt.JCRT_267_17. View

19.

Fearon K, Strasser F, Anker S, Bosaeus I, Bruera E, Fainsinger R . Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489-95. DOI: 10.1016/S1470-2045(10)70218-7. View

20.

Mirghani H, Amen F, Tao Y, Deutsch E, Levy A . Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. Cancer Treat Rev. 2015; 41(10):844-52. DOI: 10.1016/j.ctrv.2015.10.001. View